Donald E Bobo Jr sold $971k of EW
CVP,Strategy/Corp Development at Edwards Lifesciences Corp. 11,340 shares at an average of $85.66, traded Jan 6, 2026, filed Jan 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$971k at market
- +10Share of holdings soldSold 26% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001225208-26-000378, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | MOption exercise Common Stock10b5-1 | +11,340 | $59.26 | $672k | 43,210 | Jan 6, 2026 |
| Jan 6, 2026 | SOpen-market sale Common Stock10b5-1 | -2,632 | $84.62 | $223k | 40,578 | Jan 6, 2026 |
| Jan 6, 2026 | SOpen-market sale Common Stock10b5-1 | -8,708 | $85.98 | $749k | 31,870 | Jan 6, 2026 |
| Jan 6, 2026 | MOption exercise Employee Stock Option (Right to Acquire)derivative10b5-1 | -11,340 | $0.00 | $0 | 34,020 | Jan 6, 2026 |
Related signals
Other insiders at Edwards Lifesciences Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $53k 619 shares | -2% | |
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $54k 619 shares | -2% | |
| 4Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $87k 1,019 shares | -3% | |
| 32Weak | Edwards Lifesciences Corp | Scott B. Ullem CVP, Chief Financial Officer | $1.1M 13,000 shares | -25% | |
| 30Weak | Edwards Lifesciences Corp | Donald E Bobo Jr CVP,Strategy/Corp Development | $974k 11,340 shares | -35% | |
| 75Notable | Edwards Lifesciences Corp | Donald E Bobo Jr CVP,Strategy/Corp Development | $2.0M 24,000 shares | -53% | |
| 48Moderate | Edwards Lifesciences Corp | Bernard J Zovighian CEO | $1.7M 22,430 shares | -21% | |
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $87k 1,019 shares | -4% | |
| 59Moderate | Edwards Lifesciences Corp | Donald E Bobo Jr CVP,Strategy/Corp Development | $954k 11,386 shares | -23% | |
| 42Moderate | Edwards Lifesciences Corp | Heisz Leslie Stone director | $218k 2,615 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.